CD22 and acute lymphoblastic leukemia: Immune-based therapies such as blinatumomab (CD3-CD19 bispecific antibody), inotuzumab ozogamicin (anti-CD22 antibody drug conjugate) and chimeric antigen receptor T-cell (CAR-T) therapy in relapse and refractory (R/R) ALL have further improved the outcomes of B-cell ALL, including Ph+ ALL [5,6,7,8,9,10,11].